Within the last decade, several novel classes of anti-myeloma therapeutics have become
available. The clinical successes achieved by thalidomide, lenalidomide, and the …

Novel therapies in myeloma : Current Opinion in Hematology Novel therapies in myeloma :
Current Opinion in Hematology Log in or Register Subscribe to journalSubscribe Get new issue …

The successful clinical development of thalidomide, bortezomib, and lenalidomide not only
transformed the therapeutic management of multiple myeloma (MM) but also catalyzed a …

Novel Targeted Agents in the Treatment of Multiple Myeloma - Hematology/Oncology
Clinics Skip to Main Content Advertisement Hematology/Oncology Clinics Log in Register …

Advances in the molecular understanding of myeloma have led to the development of novel
agents such as immunomodulatory drugs (IMiDs) and proteasome inhibitors (bortezomib) …

The outcome of multiple myeloma has substantially improved over the past decade, mainly
due to recently approved drugs, such as thalidomide, lenalidomide, and bortezomib …

In 2004, multiple myeloma was diagnosed in more than 15,000 peoplein the United States
and will account for approximately 20% of deathsdue to hematologic malignancies …

Multiple myeloma (MM) is a clonal B-cell malignancy characterized by aberrant expansion of
plasma cells within bone marrow and extramedullary sites. In 2009, 20,580 new cases of …

Introduction: Multiple myeloma (MM) is a hematologic malignancy characterized by
proliferation of malignant plasma cells. patient outcome has improved markedly over the last …

Despite advances in the first-line treatment of multiple myeloma, almost all patients
eventually relapse, become chemoresistant, and die of the disease. Improved …